Filing Details
- Accession Number:
- 0001179110-13-012614
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-08-02 17:46:39
- Reporting Period:
- 2013-08-01
- Filing Date:
- 2013-08-02
- Accepted Time:
- 2013-08-02 17:46:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1436304 | Kythera Biopharmaceuticals Inc | KYTH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1559582 | D Jeffrey Webster | C/O Kythera Biopharmaceuticals, Inc. 27200 West Agoura Road, Suite 200 Calabasas CA 91301 | Senior Vp, Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-08-01 | 4,000 | $0.76 | 4,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-08-01 | 4,000 | $26.76 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2013-08-01 | 4,000 | $0.00 | 4,000 | $0.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 74,761 | 2017-03-13 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
- 100% of the shares subject to the option are fully vested and exercisable.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.5106 to $27.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
